comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, Health Cardiovascular outcomes trials for GLP-1
Description
GLP-1 weight-loss drugs are cutting calories and grocery bills, according to a new study from Cornells SC Johnson College of Business using data from Numerator
Most insurance plans deny Ozempic coverage for weight loss alone and require a type 2 diabetes diagnosis for approval
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Buckley A, Suliman S, Allum M, et al
For the present analysis, the team selected a subset of 111,646 overweight and obese women (BMI 25, median age 61 years) aged 45-80 years
